Results 221 to 230 of about 7,958,059 (273)

Impact of dermatology targeted immunotherapies on autoimmune thyroid diseases: cytokine-network crosstalk and thyroid safety. [PDF]

Front Immunol
Zhou J, Han R, Gao T.
europepmc   +1 more source

Clinical practice guideline for psoriasis management in Latin America. [PDF]

An Bras Dermatol
Valenzuela F, Castro Ayarza JR, Kaplan D, Londoño-García AM, Macías García KDR, Magariños G, Rivas Záldivar ES, Franco M, Cano S, Cortés C, Cárdenas PJ, Castro C, Ferreira R, Martínez S, Ibatá Bernal L, Castillo JC, Ospina J.   +16 more
europepmc   +1 more source

Interleukin (IL)-12/23 and IL-23 Inhibitors

, 2022
Biologic therapies have transformed the treatment of moderate-to-severe psoriasis. This is a rapidly evolving field, with several new monoclonal antibody medications reaching the market over the last few years. A number of classes of biologic agents now exist, corresponding to the underlying cytokine target of the antibody therapy. The interleukin (IL)-
Earnshaw, Charles, Warren, Richard B.
openaire   +3 more sources

Differentiating IL-23 Inhibitors in Crohn’s Disease

Drugs
Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory bowel disease (IBD). Therapies targeting the p19 subunit of IL-23 have recently expanded the therapeutic options for IBD demonstrating efficacy and safety for ...
Olga Maria Nardone, Sudheer K. Vuyyuru, Yuhong Yuan, Jurij Hanzel, Vipul Jairath   +4 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Biologics update: IL‐23 inhibitors

Dermatological Reviews, 2021
AbstractIntroductionIL‐23 inhibitors have shown long‐term efficacy and safety for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has also been approved to treat psoriatic arthritis while tildrakizumab and risankizumab are currently under investigation for treating psoriatic arthritis.
Julie Hong, Edward Hadeler, Megan Mosca, Mimi Chung, Samuel Yeroushalmi, Marwa Hakimi, Wilson Liao, Tina Bhutani   +7 more
openaire   +1 more source

Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors

Current Dermatology Reports, 2021
The purpose of this article is to review clinical trials evaluating the efficacy and safety of IL-23 inhibitors in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Guselkumab, tildrakizumab, and risankizumab have been approved for the treatment of psoriasis. Mirikizumab is still under investigation in phase 3 studies. IL-23
Edward Hadeler, Megan Mosca, Julie Hong, Nicholas Brownstone, Tina Bhutani, Wilson Liao   +5 more
openaire   +1 more source

IL-23 Inhibitors for Psoriasis

Current Dermatology Reports, 2018
The purpose of this article is to review current understanding of the role of IL-23 in psoriasis and the available results to date on clinical trials establishing the efficacy and safety of IL-23 inhibitors for use in adults with moderate-to-severe plaque psoriasis.
Kristen M. Beck, Eric J. Yang, Sahil Sekhon, Tina Bhutani   +3 more
openaire   +1 more source

IL-23 inhibitors for moderate-to-severe psoriasis

Seminars in Cutaneous Medicine and Surgery, 2018
Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit.
Erin, Ibler, Kenneth B, Gordon
openaire   +2 more sources

Anti‐drug antibodies of IL‐23 inhibitors for psoriasis: a systematic review

Journal of the European Academy of Dermatology and Venereology, 2022
AbstractAnti‐drug antibodies (ADAs) can form with certain biological medications, but their clinical significance is not fully understood. ADA formation in psoriasis patients treated with IL‐23 inhibitors was evaluated, looking at the incidence of ADAs, impact on clinical outcomes and association with adverse events.
Norden, A, Moon, J Y, Javadi, S S, Munawar, L, Maul, Julia-Tatjana, Wu, J J   +5 more
openaire   +3 more sources

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults

Expert Review of Clinical Immunology, 2020
Guselkumab is a subcutaneously administered human monoclonal antibody, selectively blocking IL-23 through binding to its p19 subunit. It was initially approved for the treatment of patients with moderate-to-severe plaque-psoriasis who are candidates for systemic therapy or phototherapy.
Boehncke, Wolf-Henning, Brembilla, Nicolo, Nissen, Michael John   +2 more
openaire   +5 more sources